( PDF ) Rev Osteoporos Metab Miner. 2018; 10 (1): 37-40
2 Servicio de Urología
3 Servicio de Anatomía Patológica
Hospital Universitario Cruces – Baracaldo (España)
Prostate cancer is the most common non-cutaneous malignant lesion in males over 70 years of age. Diagnosis in advanced stages of the disease is not exceptional, through metastatic lesions as debut. The most characteristic of these lesions are osseous with osteoblastic behavior, uncommon in maxillary bones.
On the other hand, Paget’s disease is a chronic metabolic disorder attributed to osteoclast dysfunction. At the craniofacial level, the characteristic affectation is an increase in size, a “cotton flakes” pattern or circumscribed osteoporosis. The fact that this is only located in the mandible is exceptional.
A case of Paget’s disease of the right hemi-mandible bone is presented in which a metastasis is developed due to prostatic adenocarcinoma.
Key words: Paget’s bone disease, osteitis deformans, prostate cancer, metastasis, oral neoplasms.
Prostate cancer (PC) is the most common non-cutaneous malignant lesion in men over 70 years. There is genetic predisposition and several exogenous factors have been proposed, but without sufficient evidence to recommend lifestyle changes that might prevent PC. Screening programs are controversial, by digital rectal examination and prostate-specific antigen (PSA) levels, with individualized strategies suggested based on the risk profile. The eco-guided biopsy is standard for diagnosis, corresponding in more than 95% of cases to acinar cell adenocarcinoma1.
On the other hand, Paget’s disease of bone (PDB) is a chronic condition of unknown cause due to osteoclast dysfunction, with increased bone remodeling that triggers bone growth and disfigurement. It presents genetic susceptibility, is more predominant in Caucasians, slightly more frequent in males and exceptional in individuals under 40 years. No cure has been found, although bisphosphonates are usually prescribed depending on metabolic activity and symptomatology2-5.
Clinical Case Report
A 77-year-old man, ex-smoker of 20 packs per year, ex-drinker of 7 units of standard drink/day until 2 years previous, and with a history of high blood pressure, ischemic stroke and intervening left carotid stenosis. His treatment was standard with atorvastatin, valsartan, hydrochlorothiazide and clopidogrel reported. He was diagnosed with stage IV prostate adenocarcinoma Gleason 3+4, with PSA values of 110.47 ng/mL and alkaline phosphatase (FA) of 142 U/L initially, and bone metastases in vertebrae C7 and D1. The serum levels of calcium, phosphorus and parathyroid hormone were within normal limits and treatment began with complete androgen blockade. After 19 months, he presented right hemifacial swelling, with bulging of both cortical of the ipsilateral mandible branch (Figure 1) and without ulceration of the oral mucosa upon examination. The pathological anatomy provides a new diagnosis of PDB in mixed phase, without data suggestive of malignancy (Figure 2). There is no suspicion of involvement in other skeletal regions.
He did not receive treatment for symptomatic stability until 11 months later, when the maxillofacial clinic is accentuated. Radiologically, sclerotic intensification with mandibular bone growth, soft tissue increases in masticatory space, as well as lymphadenopathies in right cervical Ia and Ib levels (Figure 3). A new submucosa biopsy of soft tissues and bone showed fibrous tissue with changes of sclerosis and intense artifact, with infiltration by malignant cells of epithelial aspect positive for CK, AE1/AE3 and PSA. In addition, he is diagnosed with a new bone metastasis at the level of the left iliac blade. Chemotherapy is ruled out, and two doses of 20 Gy of radiotherapy are applied with an antalgic intention in the jaw and pelvis.
After 9 months, in a control bone scan, new metastatic foci are seen in right orbit, ribs on both sides, sacral column, left humerus, both scapulae and right femoral diaphysis. He underwent surgery with intramedullary rod for femoral neck fracture. The patient died 46 months after the initial oncological diagnosis, following prolonged bed rest at home.
According to the literature, 3% of intraoral malignant lesions correspond to metastasis. The most frequent regions affected are the mandible in the molar area, with its rich vascular supply and a remnant of bone marrow in adults and the gum adhered to soft tissues. In many cases, these are late complications of advanced malignant disease with multiple visceral metastases, although up to 25% of cases are the first manifestation. Globally, the most common primary cancers in the maxillary bones are those of the breast, while in soft tissues they are those of the lung. In males, maxillary metastases of prostatic origin correspond to 11%, versus 1.5% in soft tissues. Inflammation, pain, sensitive alterations of relatively rapid evolution, or a bleeding exophytic hyperplastic lesion are usually the usual symptoms, which can easily be misinterpreted as benign pathology. The histology may simulate primary intraoral neoplasms, especially those poorly differentiated originating in salivary glands, requiring additional immune-histochemical and molecular techniques6,7.
In cases of PC, the Gleason scale allows, together with the TNM staging, to establish risk groups. To assess the locoregional extension, magnetic resonance is generally employed, while for remote extension, computed tomography and bone scintigraphy are used, where the most characteristic metastases are located1. PC cells frequently secrete factors that promote bone formation, such as bone morphogenic proteins (BMPs), and RANK-L inhibitors, attenuating osteoclastic action6. Therefore, most metastases will be osteoblastic although they have also been reported in a mixed, osteolytic form, even without radiological evidence. As with other mandibular neoplasms, diagnosis is not unusual after pain or paresthesia-hypoesthesia of the inferior dental nerve that does not improve after dental treatments8-11. They have not only been reported at mandibular level, but also in branches12, condyles13 and parotid glands with bone infiltration14.
The number and location of bone metastases in PC are among the most commonly used but not validated prognostic factors, in addition to visceral metastases, the Gleason score, PSA and AF. The usual management is androgen blockade combined or not with chemotherapy. The prescription of bisphosphonates, radiotherapy, even cytoreductive surgeries or metastasectomies to improve quality of life is recognized for palliative purposes1.
As for PDB, the location is segmental, monostotic or polyostotic, most common in the pelvis, femur, spine, skull and tibia, although it can affect any bone and may present with pain, arthralgias and compression syndromes. There is an increased risk of fracture and malignancy. It is asymptomatic in many cases, carrying out the diagnosis when complications appear or characteristic radiological images. The Paget-affected bone presents vascular alterations, with regional vasodilatation, which could increase cardiovascular risk. The bone scan allows us to assess the extension. In the active phase of the disease, though not a specific datum, serum FA increases along with other replacement markers. Histology usually shows a mosaic pattern, with areas of osteoclastic and osteoblastic activity. Multinucleated osteoclasts and cytoplasmic or intranuclear inclusions are more typical of the initial rest phase. In addition, it presents with bone marrow fibrosis and arterio-venous shunts3-5.
Increased cranial size, a “cotton flakes” pattern or circumscribed osteoporosis, are the most characteristic findings at the head level of the PDB, with singular mandibular involvement considered exceptional. The teeth erupt mispositioned and migrate with bone growth, showing in radiographs both radiolucent areas as of hypercementosis or ankylosis of roots. In these cases, the extractions are complex, alveolar healing is slow with localized osteitis, and there is an increased risk of secondary osteomyelitis. Loco-regional surgical remodeling has its role, and additional precautions should be taken to control haemostasis and infections with optional oral surgery5,15,16.
Bisphosphonates slow the differentiation of common precursor cells, promote apoptosis and suppress bone resorption by osteoclasts, hence their indication in active PDB and in symptomatic bone metastases. They also have anti-angiogenic properties and a half-life of up to 11 years after bone incorporation. Before starting treatment, whatever the disease and route of administration, a dental examination and extraction of periodontal teeth on or adjacent to the lesion, in order to prevent osteonecrosis are recommended2,17-19.
The main differential diagnoses of craniofacial PDB are fibrous dysplasia and fibro-osteomas5. In the present case, as there was a recent change in the lesion with a soft-tissue component, sarcomatoid malignancy would also be included, with osteonecrosis being less likely due to the lack of a history of bisphosphonates, anti-angiogenesis and radiotherapy. However, due to the vascular alterations and the compromised scarring of the Pagetic bone, spontaneous osteonecrosis could be triggered20. Although the patient developed unfavorably, it has been shown that PC and PBD association delays metastatic progression and increases overall survival21.
Metastatic PC is not uncommon in our setting, with a high survival rate. The mandibular location of this oncological or other lineage is a challenge for both clinicians and pathologists. Occasionally, the overlap of bone disease can hinder diagnosis even more, highlighting metabolic disorders, both training and recovery, and the side effects of therapies, such as osteonecrosis.
Conflict of interests: The authors declare no conflicts of interest.
The precepts of the Helsinki declaration on clinical studies have been observed throughout this research work.
2. Corral-Gudino L, Tan AJ, Del Pino-Montes J, Ralston SH. Bisphosphonates for Paget’s disease of bone in adults. Cochrane Database Syst Rev. 2017;12:CD004956.
3. Torrijos A. Enfermedad ósea de Paget. Rev Osteoporos Metab Miner. 2014;6(4):77-8.
4. Lisbona MP, Blanch-Rubió J, Galisteo C, Esquerra E, Monfort J, Ciria M, et al. Epidemiología de la enfermedad ósea de Paget en un área de Barcelona. Rev Osteoporos Metab Miner. 2009;1(1):7-12.
5. Cooke BED. Paget´s Disease of the Jaws: Fifteen Cases. Ann R Coll Surg Engl. 1956;19(4):223-40.
6. Kumar GS, Manjunatha BS. Metastatic tumors to the jaws and oral cavity. J Oral Maxillofac Pathol. 2013;17(1):71-5.
7. Hirshberg A, Shnaiderman-Shapiro A, Kaplan I, Berger R. Metastatic tumours to the oral cavity-pathogenesis and analysis of 673 cases. Oral Oncol. 2008;44(8):743-52.
8. Aksoy S, Orhan K, Kursun S, Kolsuz ME, Celikten B. Metastasis of prostate carcinoma in the mandible manifesting as numb chin syndrome. World J Surg Oncol. 2014;12(1):401.
9. Menezes JDS, Cappellari PFM, Capelari MM, Gonçalves PZ, Toledo GL, Toledo Filho JL, et al. Mandibular metastasis of adenocacinoma from prostate cancer: case report according to epidemiology and current therapeutical trends of the advanced prostate cancer. J Appl Oral Sci. 2013;21(5):490-5.
10. Parkins GE, Klufio GO. Prostate cancer metastasis to the mandible: case report. East Afr Med J. 2009;86(5):251-2.
11. Court DR, Encina S, Levy I. Prostatic adenocarcinoma with mandibular metastatic lesion: Case report. Med Oral Patol Oral Cir Bucal. 2007;12(6):E424-7.
12. Angulo JC, López JI, Ruiz de Galarreta JC, Larrinaga JR, Flores N. Carcinoma of the prostate metastasized to mandible simulating primary parotid tumor. Arch Esp Urol. 1993;46(2):143-4.
13. Eres Saz FJ, Camps C, Sarmentero Ortiz E, Colomer F, Zaragoza J. Mandibular metastasis as the first manifestation of adenocarcinoma of the prostate. Actas Urol Esp. 1989;13(4):274-5.
14. Head CS, Hematpour K, Sercarz J, Luu Q, Bennett CJ. Carcinoma of the prostate presenting as a painful parotid mass with mandibular invasion: a case report. Ear Nose Throat J. 2009;88(12):E7-8.
15. Umamaheswari G, Pangarikar AB, Urade VB, Parab PG. Management of craniofacial osteitis deformans. Ann Maxillofac Surg. 2014;4(2):243-6.
16. Shankar YU, Misra SR, Baskaran P. Paget disease of bone: A classic case report. Contemp Clin Dent. 2013;4(2):227-30.
17. García M, Torrijos A. Tratamiento de la enfermedad ósea de Paget. Rev Osteoporos Metab Miner. 2011;3(1):35-40.
18. Joshi J, Rollón A, Coello, Lledó E, Lozano R, Sanchez-Moliní M, et al. Osteonecrosis de los maxilares asociada al uso de bifosfonatos: revisión de ocho casos. Rev Esp Cir Oral Maxilofac. 2011;33(1):15-21.
19. Şalvarcı A, Altınay S. Mandibular osteonecrosis due to bisphosphonate use. Turk J Urol. 2015;41(1):43-7.
20. Polisetti N, Neerupakam M, Prathi VS, Prakash J, Vaishnavi D, Beeraka SS, et al. Osteonecrosis Secondary to Paget´s Disease: Radiologic and Pathologic Features. J Clin Imaging Sci. 2014;4(Suppl 2):1.
21. Tu S-M, Som A, Tu B, Logothetis CJ, Lee M-H, Yeung S-CJ. Effect of Paget´s disease of bone (osteitis deformans) on the progression of prostate cancer bone metastasis. Br J Cancer. 2012;107(4):646-51.